Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.
Using checkpoint inhibitor therapy before CAR T treatment works in practice for rare aggressive lymphoma, giving clinicians a tested strategy.
This real-world study evaluated the use of pembrolizumab as holding and bridging therapy before CAR T-cell therapy in R/R PMBCL patients, providing clinical data for a treatment strategy that leverages checkpoint inhibition to optimize patients prior to CAR T infusion. Results inform clinical practice for this rare aggressive lymphoma subtype.
What the study was
- Study design
- Retrospective real-world study
- Population
- Relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBCL) patients receiving CAR T-cell therapy
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International Journal of Clinical Oncology
Why it surfaced
Real-world data on pembrolizumab bridging for CAR T in PMBCL; adds to growing evidence base for optimizing CAR T delivery.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.